Back to News
Apr 8, 2026 8:00 AM

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced that it has raised $5 million in additional funds for its Series B financing from new investor Hatteras Venture Partners. As part of the financing, Hatteras partner Kseniya Simpson, Ph.D., will join the Company's board of directors and Hatteras general partner Christy Shaffer, Ph.D., will join as a board observer.

"We are encouraged by Hatteras's strong enthusiasm for our CDK2 program and their support in advancing INX-315 toward meaningful clinical outcomes," said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer ...